Passage Bio Stock (NASDAQ:PASG), Analyst Ratings, Price Targets, Predictions

The latest price target for Passage Bio (NASDAQ: PASG) was reported by Canaccord Genuity on March 5, 2024. The analyst firm set a price target for $14.00 expecting PASG to rise to within 12 months (a possible 858.90% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Passage Bio (NASDAQ: PASG) was provided by Canaccord Genuity, and Passage Bio reiterated their buy rating.

There is no last upgrade for Passage Bio.

The last downgrade for Passage Bio Inc happened on March 8, 2022 when JP Morgan changed their price target from N/A to N/A for Passage Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on March 5, 2024 so you should expect the next rating to be made available sometime around March 5, 2025.

While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a reiterated with a price target of $0.00 to $14.00. The current price Passage Bio (PASG) is trading at is $1.46, which is within the analyst’s predicted range.